FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

NCI Sees Revumenib Promise for Some Leukemias

[ Price : $8.95]

The National Cancer Institute says Syndax Pharmaceuticals revumenib shows promise in treating some acute myeloid leukemias.

FDA Cautions Compounders on Bulk Sources

[ Price : $8.95]

FDA says drug compounders should be sure the active pharmaceutical ingredients and excipients they use have been evaluated by thei...

FDA Drug Inspections Slow to Recover: Analysis

[ Price : $8.95]

ProPublica says FDA foreign drug manufacturer inspections remain well below pre-pandemic inspection levels.

Guidance Shows Importance of Sponsor Oversight: Attorneys

[ Price : $8.95]

Sidley attorneys say a new FDA final guidance on a risk-based approach to clinical trial oversight is significant for trial sponso...

Generic Mifepristone Maker Sues FDA

[ Price : $8.95]

Generic mifepristone maker GenBioPro sues FDA to block the agency from taking any actions against the company if a pending court o...

FDA OKs Qulipta Expanded Indication

[ Price : $8.95]

FDA approves an expanded indication for AbbVies Qulipta to prevent chronic migraines.

High Court Adds 2 Days to Mifepristone Stay

[ Price : $8.95]

The U.S. Supreme Court extends by two days (until 4/21) its administrative stay of a lower courts 4/7 order that would restrict th...

EMA/FDA Bioequivalence Info Sharing Pact Adds Ireland

[ Price : $8.95]

An ongoing European Medicines Agency and FDA joint initiative on information sharing involving generic drug bioequivalence study i...

FDA OKs Traditional Approval for Genentechs Polivy

[ Price : $8.95]

FDA grants traditional approval of Genentechs Polivy (polatuzumab vedotin-piiq) for combination use with four other drugs in for t...

House Oversight Panel Puts Heat on FDA Over CBD

[ Price : $8.95]

House Committee on Oversight and Accountability chairman James Comer begins probe into FDAs recent decision not to regulate cannab...